We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

115 hedge funds and large institutions have $867M invested in Coherus Oncology in 2018 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 48 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 25

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

58% more call options, than puts

Call options by funds: $14.6M | Put options by funds: $9.23M

42% more capital invested

Capital invested by funds: $611M → $867M (+$256M)

12% more funds holding

Funds holding: 103 → 115 (+12)

2.9% more ownership

Funds ownership: 91.94% → 94.83% (+2.9%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
115
Holders Change
+12
Holders Change %
+11.65%
% of All Funds
2.63%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
48
Reduced
25
Closed
15
Calls
$14.6M
Puts
$9.23M
Net Calls
+$5.39M
Net Calls Change
+$4.38M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$12.1M
2
BlackRock
BlackRock
New York
+$11.6M
3
HP
Hound Partners
New York
+$11.1M
4
Deutsche Bank
Deutsche Bank
Germany
+$9.04M
5
MWNA
Marshall Wace North America
New York
+$8.95M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.47M
2
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$4.15M
3
HCM
Highbridge Capital Management
New York
-$4.14M
4
SFM
Sphera Funds Management
Israel
-$2.98M
5
Ameriprise
Ameriprise
Minnesota
-$2.74M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$108M -$774K -54,061 -0.7%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$96.5M -$8.47M -591,923 -8%
Temasek Holdings
3
Temasek Holdings
Singapore
$91.8M – – –
BlackRock
4
BlackRock
New York
$58M +$11.6M +810,358 +24%
KKRC
5
Kohlberg Kravis Roberts & Co
New York
$42.8M – – –
SI
6
Sofinnova Investments
California
$40.5M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$31.9M +$3.06M +213,759 +10%
JP Morgan Chase
8
JP Morgan Chase
New York
$31.3M +$2.69M +187,830 +9%
Citadel Advisors
9
Citadel Advisors
Florida
$29.5M +$5.77M +402,929 +24%
State Street
10
State Street
Massachusetts
$29.5M +$2.68M +187,305 +10%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$24M +$3.19M +222,857 +15%
O
12
OrbiMed
New York
$20.7M +$196K +13,682 +0.9%
Deutsche Bank
13
Deutsche Bank
Germany
$18.4M +$9.04M +631,718 +92%
UBS AM
14
UBS AM
Illinois
$18.4M -$119K -8,297 -0.6%
TCIM
15
TIAA CREF Investment Management
New York
$15.9M +$1.02M +71,392 +7%
FCM
16
Farallon Capital Management
California
$11.8M +$12.1M +845,000 New
HP
17
Hound Partners
New York
$10.9M +$11.1M +778,508 New
TA
18
Teachers Advisors
New York
$10.3M +$8.75M +611,309 +496%
RSCM
19
Rock Springs Capital Management
Maryland
$9.66M -$71.6K -5,000 -0.7%
MWNA
20
Marshall Wace North America
New York
$8.96M +$8.95M +625,100 +4,124%
Brown Advisory
21
Brown Advisory
Maryland
$8.88M -$56.3K -3,933 -0.6%
Northern Trust
22
Northern Trust
Illinois
$7.93M +$1.28M +89,400 +19%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$7.1M +$1.02M +71,097 +16%
Millennium Management
24
Millennium Management
New York
$7.05M +$4.93M +344,240 +216%
Macquarie Group
25
Macquarie Group
Australia
$6.06M +$186K +13,000 +3%
1
2 3 4 5

CHRS Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2018, worth a combined $867M — up 42% from $611M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CHRS positions and 15 closed out — a net gain of 12 holders — while 48 added to existing stakes and 25 trimmed.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $12.1M. The largest seller was Fidelity Investments, cutting an estimated $8.47M.

  • 115 institutional investors held Coherus Oncology (CHRS) as of Q2 2018, up from 103 in Q1 2018.
  • Funds reported $867M of Coherus Oncology stock for Q2 2018, up 42% quarter-over-quarter.
  • 27 funds opened new Coherus Oncology positions in Q2 2018 and 15 closed out, a net change of +12 holders.
  • The largest Coherus Oncology buyer in Q2 2018 was Farallon Capital Management, an estimated $12.1M added.
  • The largest Coherus Oncology seller in Q2 2018 was Fidelity Investments, an estimated $8.47M sold.

Based on aggregated 13F filings for Q2 2018.